MARKET

CRSP

CRSP

Crispr Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

110.00
+0.01
+0.01%
After Hours: 110.34 +0.34 +0.31% 19:04 11/25 EST
OPEN
110.38
PREV CLOSE
109.99
HIGH
111.38
LOW
108.51
VOLUME
405.17K
TURNOVER
--
52 WEEK HIGH
111.90
52 WEEK LOW
32.30
MARKET CAP
7.77B
P/E (TTM)
-33.8045
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CRISPR Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020, at 9:30 a.m. ET. A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.comMedia Contact: Rachel Eides WCG on behalf of CRISPR +1-617-337-4167 reides@wcgworld.com
GlobeNewswire · 2d ago
CRISPR scientists claim they identified human genes that can protect against Covid-19
A team of CRISPR scientists in New York say they have identified the genes that can protect human cells against Covid-19.
CNBC.com · 6d ago
CRISPR Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the Jefferies London Healthcare Conference on Thursday, November 19, 2020, at 12:00 p.m. ET. A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.comMedia Contact: Rachel Eides WCG on behalf of CRISPR +1-617-337-4167 reides@wcgworld.com
GlobeNewswire · 11/16 13:00
Healthcare rallies as Presidential vote count continues
The vote count to decide the next U.S. commander-in-chief is ongoing but healthcare investors do not appear concerned about who will eventually prevail since most industries are up in lockstep
Seekingalpha · 11/04 17:12
CRISPR/Cas9 Gene-Editing Therapy CTX001 For Severe Hemoglobinopathies Accepted For Plenary Presentation At 62nd American Society Of Hematology Meeting And Exposition
CRISPR/Cas9 Gene-Editing Therapy CTX001™ for Severe Hemoglobinopathies Accepted for Plenary Presentation at the 62nd American Society of Hematology (ASH) Meeting and Exposition ZUG, Switzerland and CAMBRIDGE,
Benzinga · 11/04 14:17
CRISPR Therapeutics sitting on $1.3B in quick assets to fund pipeline development
CRISPR Therapeutics (CRSP) reported Q3 results this morning. Fundamentals continue to reflect its clinical-stage status. Funding should not be a near-term concern considering its $1.3B balance of cash (~$1B) and
Seekingalpha · 10/28 13:21
CRISPR Therapeutics EPS misses by $0.13, misses on revenue
CRISPR Therapeutics (CRSP): Q3 GAAP EPS of -$1.32 misses by $0.13.Collaboration revenue of $0.15M (-99.9% Y/Y) misses by $2.07M.Cash, equivalents and marketable securities of $1.4B.Shares -3.18% PM.Press Release
Seekingalpha · 10/28 12:10
CRISPR Therapeutics Q3 EPS $(1.32) Down From $2.40 YoY, Sales $148.00K Down From $211.93M YoY
CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.32) per share. This is a 155 percent decrease over earnings of $2.40 per share from the same period last year. The company reported $148.00 thousand in
Benzinga · 10/28 12:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRSP. Analyze the recent business situations of Crispr Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRSP stock price target is 102.63 with a high estimate of 140.00 and a low estimate of 45.00.
EPS
Institutional Holdings
Institutions: 412
Institutional Holdings: 50.11M
% Owned: 70.92%
Shares Outstanding: 70.65M
TypeInstitutionsShares
Increased
92
10.86M
New
98
1.25M
Decreased
85
3.62M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/President/Co-Founder/Director
Rodger Novak
Chief Executive Officer/Director
Samarth Kulkarni
Chief Financial Officer
Michael Tomsicek
Chief Operating Officer
Lawrence Klein
Executive Vice President
Tony Ho
General Counsel/Secretary
James Kasinger
Independent Director
Ali Behbahani
General Counsel/Secretary
Jim Kasinger
Independent Director
Bradley Bolzon
Independent Director
Simeon George
Independent Director
John Greene
Independent Director
Katherine High
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Crispr Therapeutics AG stock information, including NASDAQ:CRSP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRSP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRSP stock methods without spending real money on the virtual paper trading platform.